검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD22 CAR |
Overview Company | Matthew Frank |
Overview Modality | CGT |
Overview Target | CD22 |
Overview Indication | B-ALL; B-cell Non Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | target off-tumor effects, and tumor antigen |
MoA Biomarker | CD19low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies.. Ex vivo chimeric antigen receptor (CAR) T cell therapy has proven successful in patients with B cell hematologic malignancies. However, current approaches are limited by the requirement for personal manufacturing processes and by barriers such as limited efficacy against solid tumors, treatmen… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 27 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD22 CAR |
Overview Company | Matthew Frank |
Overview Modality | CGT |
Overview Target | CD22 |
Overview Indication | B-ALL; B-cell Non Hodgkin Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | target off-tumor effects, and tumor antigen |
MoA Biomarker | CD19low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies.. Ex vivo chimeric antigen receptor (CAR) T cell therapy has proven successful in patients with B cell hematologic malignancies. However, current approaches are limited by the requirement for personal manufacturing processes and by barriers such as limited efficacy against solid tumors, treatmen… |
Toxicology CRS | Reported |
Clinical Data Tier / Score | A · 27 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교